Results 51 to 60 of about 8,073 (209)
Nature Communications, 2020 Phosphodiesterase-5 (PDE5) inhibitors have been suggested to have an anti-tumor effect and block surgery-induced immunosuppression. Here, the authors show that postdiagnostic use of PDE5 inhibitors is associated with a decreased risk of colorectal ...
Wuqing Huang +3 more
doaj +1 more source
Non‐canonical PKG1 regulation in cardiovascular health and disease
British Journal of Pharmacology, EarlyView.It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley +1 more source
The Journal of Sexual Medicine, 2009 ABSTRACT Introduction Oral phosphodiesterase type 5 inhibitors (PDE5i) have improved treatment options for erectile dysfunction (ED). In case of unresponsiveness to PDE5i, alternative therapies are considered.
Onder, Canguven +4 more
openaire +2 more sources
NAION in a Healthy 37-Year Old: Supporting the Association with PDE5 Inhibitors [PDF]
, 2023 Non-arteritic anterior ischemic optic neuropathy (NAION) has been previously associated with use of phosphodiesterase type 5 (PDE5) inhibitors. The proposed mechanism is that vasodilation reduces perfusion of the optic nerve with subsequent ischemia ...
Natalie Brossard-Barbosa; Zoe Williams
core
British Journal of Pharmacology, EarlyView.Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz +8 more
wiley +1 more source
Synthesis, Characterization and Screening of Pharmacologically Active Chemical Entities [PDF]
, 2007 Not ...
Khunt, Rupesh C.
core
Optimization of Substituted N-3-Benzylimidazoquinazolinone Sulfonamides as Potent and Selective PDE5 Inhibitors [PDF]
, 2016 A previous report from these laboratories identified the N-3-benzylimidazoquinazolinone nucleus as a more selective PDE5 inhibitor template compared to the pyrazolopyrimidine of sildenafil.
John Krupinski (1745206) +7 more
core +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu +4 more
wiley +1 more source
Presentation_1_Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems.PPTX [PDF]
, 2019 Human castration-resistant prostate cancer (CRPC) is a significant target of clinical research. The use of DNA-damaging agents has a long history in cancer chemotherapy but is limited by their toxicities.
Chia-Chun Yu (515081) +9 more
core +1 more source
British Journal of Pharmacology, EarlyView.Background and Purpose Metabolic dysfunction‐associated steatohepatitis (MASH) is linked to activation of hepatic stellate cells (HSCs) to α‐smooth muscle actin–positive myofibroblasts that produce collagen and proinflammatory cytokines. Quiescent HSCs express the NO‐cGMP signalling axis.
Krithika Rajeeth +14 more
wiley +1 more source